Genomic/Transcriptomic Analysis for Lymphoma

Overseen By Jason Westin, MD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: M.D. Anderson Cancer Center

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to determine how well the Molecular Functional (MF) Portrait test can assist doctors in treating lymphoma, a type of blood cancer. Researchers seek to discover if this test can guide better care for patients with diffuse large B-cell lymphoma, a common and aggressive form of lymphoma. Individuals diagnosed with diffuse large B-cell lymphoma who require treatment might be suitable for this trial. Participants will undergo the MF Portrait test, which examines the genes and activity within their cancer to help tailor treatment decisions. As an unphased trial, this study offers patients the chance to contribute to innovative research that could lead to more personalized treatment options.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What prior data suggests that the Molecular Functional Portrait is safe for guiding lymphoma care?

Research shows that the Molecular Functional Portrait test provides detailed insights into tumors, including the different types of cells and their activities. This test does not involve new drugs or treatments, so it lacks the safety concerns associated with drug trials.

The test offers a comprehensive view of the tumor's genetic information, aiding doctors in making informed decisions about treating lymphoma. As a diagnostic tool rather than a treatment, it poses minimal risk to participants. No negative effects from the test itself have been reported.

In summary, the Molecular Functional Portrait test is considered safe because it does not involve new drugs or therapies. Instead, it enhances doctors' understanding of the tumor to guide treatment decisions. ^{1 2 3 4 5}

Why are researchers excited about this trial?

Researchers are excited about the Molecular Functional Portrait because it offers a personalized approach to guiding lymphoma care. Unlike traditional treatments, which often rely on a one-size-fits-all strategy, this method uses genomic and transcriptomic analysis to tailor treatment plans to the individual's unique cancer profile. This personalized approach could potentially improve treatment effectiveness and minimize unnecessary side effects, providing a more targeted and efficient way to combat lymphoma.

What evidence suggests that the Molecular Functional Portrait is effective for guiding lymphoma care?

Research has shown that the Molecular Functional (MF) Portrait test, which participants in this trial will undergo, can guide lymphoma care by mapping a tumor's features in detail. This test combines genetic and molecular information to clarify how the cancer behaves. Understanding these features can reveal weaknesses in the cancer, potentially aiding doctors in selecting better treatments. For example, one study found that different types of lymphoma share specific genetic traits, influencing treatment choices. This testing could be crucial in tailoring lymphoma treatments to each patient's unique cancer profile. ^{1 3 6 7 8}

Who Is on the Research Team?

Jason Westin

Principal Investigator

M.D. Anderson Cancer Center

Are You a Good Fit for This Trial?

This trial is for adults over 18 with a confirmed diagnosis of diffuse large B-cell lymphoma that needs treatment. Participants must provide written consent to be part of the study.

Inclusion Criteria

Provision of written informed consent for the study

I have been diagnosed with diffuse large B-cell lymphoma and need treatment.

Exclusion Criteria

Not applicable.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Molecular Testing

Participants undergo molecular testing using the Molecular Functional (MF) Portrait to guide lymphoma care

4-6 weeks

Follow-up

Participants are monitored for safety and effectiveness after molecular testing

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Molecular Functional Portrait

Trial Overview The trial is examining the effectiveness of using a commercial test called Molecular Functional Portrait by BostonGene to guide treatment decisions in patients with lymphoma.

How Is the Trial Designed?

Group I: Molecular Testing Experimental Treatment 1 Intervention

Molecular Functional (MF) Portrait (a commercial test conducted by the sponsor of this study, BostonGene) in guiding lymphoma care.

Who Is Running the Clinical Trial?

M.D. Anderson Cancer Center

Lead Sponsor

Trials

3,107

Recruited

1,813,000+

Published Research Related to This Trial

This study utilized gene-expression profiling to analyze all major B-cell lymphoma types, identifying key survival genes and pathways that could serve as potential therapeutic targets.

The research highlighted common survival mechanisms across different lymphoma types, particularly focusing on the B-cell receptor (BCR) pathways, which revealed molecular differences within these lymphomas.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Functional signatures identified in B-cell non-Hodgkin lymphoma profiles. Aggarwal, M., Sánchez-Beato, M., Gómez-López, G., et al.[2019]

Gene expression microarrays can effectively identify subgroups of lymphoma and leukemia, correlate with cytogenetic abnormalities, and predict patient prognosis, enhancing diagnostic accuracy.

These microarrays may lead to new therapeutic targets for chemotherapy and will likely be integrated into clinical practice to tailor treatment plans based on individual gene expression profiles.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

mRNA microarray analysis in lymphoma and leukemia. Greiner, TC.[2019]

A new method called Correlated Gene Set Analysis (CGSA) was developed to analyze transcriptional data, revealing three distinct tumor profiles in a study of 364 patients with Diffuse large B-cell lymphomas.

The study identified two main profiles with high gene expression related to proliferation and immune response, while a third profile showed low gene activation similar to normal B cells, highlighting the complexity of DLBCL and its metabolic characteristics.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Massive transcriptional perturbation in subgroups of diffuse large B-cell lymphomas. Rosolowski, M., Läuter, J., Abramov, D., et al.[2021]

Gene expression profiling has identified distinct molecular subgroups within diffuse large B-cell lymphoma (DLBCL), which differ in their oncogenic mechanisms and responses to chemotherapy, highlighting the need for tailored treatment approaches.

The NF-kappaB pathway is crucial for the survival of certain DLBCL subgroups (ABC DLBCL and PMBL), suggesting it could be a potential therapeutic target, while the proliferation rate of tumors in mantle cell lymphoma significantly impacts patient survival, indicating the importance of molecular characteristics in prognosis.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The biology of human lymphoid malignancies revealed by gene expression profiling. Staudt, LM., Dave, S.[2018]

Recent advances in large-scale gene expression profiling have enabled the identification of distinct gene expression signatures in lymphomas, which can differentiate between germinal center and activated B-cell phenotypes.

This differentiation reveals that large B-cell lymphomas may actually represent two distinct diseases with significantly different responses to chemotherapy, highlighting the potential for more personalized treatment approaches based on genetic profiling.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Gene expression profiling of lymphomas. Hegde, U., Wilson, WH.[2019]

The study analyzed 156 cases of diffuse large B-cell lymphoma (DLBCL) and identified three distinct immunophenotypic groups using immunohistochemistry, which were then correlated with gene expression profiles obtained from microarray analysis.

Gene expression profiling revealed that DLBCL can be molecularly subgrouped, with Group B lymphomas showing unique gene expression patterns that suggest additional factors beyond cell-of-origin may influence their development, indicating a complex pathogenesis.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Gene expression profiling of diffuse large B-cell lymphoma in China]. Liu, YH., Li, L., Liu, G., et al.[2016]

Non-Hodgkin's lymphomas are a diverse group of diseases that can be subclassified based on the differentiation of malignant B cells and specific genetic abnormalities, highlighting the complexity of these cancers.

Gene expression profiling reveals significant molecular differences within non-Hodgkin's lymphomas, which can influence tumor behavior and patient outcomes, suggesting that understanding these signatures can improve prognostication and treatment strategies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Gene expression signatures and outcome prediction in mature B-cell malignancies. Dave, SS.[2019]

Citations

1. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC12047492/

A patient-derived T cell lymphoma biorepository uncovers ... A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities.

2. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC5395128/

Integrative clinicopathological and molecular analyses of ... We found that F-PTCL and other nodal PTCL with TFH phenotype share not only immunophenotypical features, but also similar clinical, genetic and molecular ...

3. sciencedirect.com sciencedirect.com/science/article/pii/S0006497124001046

The follicular lymphoma tumor microenvironment at single ... Over time, FL evolves into pathological variants associated with distinct outcomes, ranging from an indolent disease to more aggressive clinical ...

4. science.bostongene.com science.bostongene.com/tumor-portrait/

Athena Molecular Functional Tumor Portrait A planetary schematic representation of the molecular and functional characteristics of a tumor based on integrated genomics and transcriptomics.

5. ashpublications.org ashpublications.org/blood/article/146/15/1812/537307/An-updated-understanding-of-follicular-lymphoma

An updated understanding of follicular lymphoma transformation Clinical outcome data for new regimens in patients with tFL are often limited, given that patients with transformed indolent histologies are ...

6. cell.com cell.com/cancer-cell/fulltext/S1535-6108(21)00222-1

Conserved pan-cancer microenvironment subtypes predict ... A visual tool integrating transcriptomic and genomic data provides a global tumor portrait, describing the tumor framework, mutational load, ...

7. mdpi.com mdpi.com/2072-6694/14/14/3434

Classifying Germinal Center Derived Lymphomas— ... Molecular classification schemes, first of all, derived from whole transcriptome gene expression data largely improved subtyping and functional understanding.

8. github.com github.com/BostonGene/MFP

BostonGene/MFP: Mollecular Functional Portraits Data preparation. Data retrieval (and normalization). Quality Check (QC). Batch detection; Outliers detection; Data distribution check for data quality.